Core Viewpoint - Xianle Health is strategically shifting its focus towards overseas markets by planning an IPO in Hong Kong, aiming to become the first A+H listed company in its industry, while divesting from underperforming segments to enhance its global presence [2][3][15]. Financial Performance - Domestic business revenue reached 818 million CNY, showing a year-on-year decline of 1.63%, indicating a stagnant performance [2]. - In contrast, overseas business revenue was 1.224 billion CNY, experiencing a growth of 5.58%, highlighting its role as a key profit driver [2]. Strategic Moves - The company has established seven production bases and five R&D centers across China and Europe, ensuring a comprehensive supply chain from product development to logistics [6]. - Recent infrastructure upgrades include the opening of a smart logistics center in Shantou and an industrial park in Thailand, enhancing its cross-border e-commerce capabilities [10]. Market Trends - The global health food market is projected to reach 226.8 billion USD by 2026, driven by trends such as aging populations and the increasing prevalence of chronic diseases among younger individuals [11]. Divestment Strategy - Xianle Health has decided to sell its subsidiary BFPC, which has incurred losses of nearly 380 million CNY over three and a half years, to streamline operations and focus on more profitable ventures [13]. IPO Plans - The upcoming IPO in Hong Kong is aimed at raising funds for R&D, digital transformation, and capacity expansion, with a focus on leveraging AI for precision nutrition and building smart factories [14]. - The company's strategy of divesting unprofitable segments while capitalizing on overseas business growth positions it favorably for the IPO and future market opportunities [15].